"Financing-based Cooperation"
On December 11, 2025, Illumina announced that it had completed the acquisition of MyOme.Strategic Investment and Deep Cooperation Achieved。This collaboration will accelerate MyOme's core roadmap, including the launch of a large-scale prospective study — the MyOme Proactive Health (MPH) trial, which aims to prove"Whole Genome Sequencing (WGS) + MyOme AI Integrated Risk Model (IRM)"In the fields of common chronic diseases, cancer, and rare diseases, it can significantly improve patient outcomes and bring about substantial cost savings.Uh, the title we saw at the beginning, "$200 billion saved annually...," almost made me think that Illumina had invested $200 billion in MyOme.Illumina did not disclose the investment amount this time. Shah only revealed that the funds will be used to expand MyOme's R&D and commercial teams, including early access to new products in Illumina’s pipeline and corresponding business opportunities.What is particularly interesting here is that MyOme will need to use Illumina's NovaSeq X sequencer and reagents for its MPH clinical trial.However, the money for these instruments and reagents comes from Illumina's investment (in part).Don't you feel very familiar with it?Isn't this the same as the circular financing in the AI circle...Of course, this method of play existed long ago.Moreover, MyOme's current round of financing has continued to receive support from Natera, a global leader in genetic testing, and top-tier capital firms like Sequoia have also followed up with investments.So, what exactly is MyOme?In 2003, Matthew Rabinowitz's sister gave birth to a baby with Down syndrome, who unfortunately passed away 6 days later.Matthew Rabinowitz came up with an idea to prevent such tragedies through prenatal screening.Thus, Natera was born in 2005.Actually, you don't have to envy him. This guy started his business in 1998.Matthew Founded Panopticon (panop.com) in 1998, an online shopping recommendation algorithm company.Later, it was acquired by Broadbase for $108 million in 2000.In 2017, he founded today's protagonist, MyOme, out of restlessness.Currently, only two rounds of financing can be found, and only the B-round financing of 23 million US dollars is known, the rest are unclear."The Elephant in the Room"
Friends who are familiar with the U.S. healthcare system all know that medical care in the U.S. is expensive, difficult to access, and medications are costly.Using medications without professional guidance may not only be ineffective but could also lead to drug abuse.The entire healthcare system has no choice but to pay the price for this distortion, and this distortion continues to self-perpetuate.That's the elephant in the room—everyone sees it but no one has a better solution to address it.MyOme's philosophy is to precisely stratify and分流 potential patients through genetic testing (or the integration of multi-omics).Thereby reducing unnecessary medical waste and streamlining the processes of the healthcare system.I would even understand it as an enhanced version of 23andMe, providing not only genetic information but also medical solutions.Can also provide diagnosis of rare diseases and has its own CLIA/CAP certified laboratory.So, can this set of logic achieve a closed loop?I have reservations and won't elaborate.December 15, 2025，MyOme Collaborates with Thatch to Launch Thatch's First Genomics Solution.The partnership will integrate MyOme's genome-based proactive health reports into Thatch Marketplace, allowing members to access cutting-edge health insights more conveniently.Thatch is a modern health benefits platform company headquartered in the United States, founded in 2021 by Chris Ellis and Adam Stevenson. It primarily serves startups, helping employers set up flexible, tax-free health benefits for employees within 5 minutes.。On August 12, 2025, MyOme also partnered with Mayo Clinic's accelerator program, gaining access to five-year longitudinal de-identified data from approximately 3 million patients to validate and enhance the performance of its IRM (Integrated Risk Model) covering over 20 rare and common diseases.Is MyOme about to go public?Finally, let's summarize.MyOme is a genomics company that advances precision health through whole-genome sequencing and AI-integrated risk models. Its core philosophy is to reduce the overall healthcare burden on society by ensuring the right person receives the right treatment (and the right medical plan).Illumina Invests in MyOme, MyOme Purchases Instruments and Reagents from Illumina, We All Have a Bright Future.
| 
